InsidersTradesSigma
Opus Genetics, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Opus Genetics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.9bn. The latest transaction was reported on 27 July 2026 (Cession). Among the most active insiders: Magrath George. Every trade is accessible without an account.
76
Insider Decl.
n/a
Thresholds
€325,939
4 ops.
Buy Volume
€8m
15 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Opus Genetics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$56.73.
56Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 July 2026
Declarations76 total
7,783 shares@ US$2.9477Common StockSEC:0000905148-26-003351:0
9,475 shares@ US$2.9473Common StockSEC:0000905148-26-003352:0
4,644 shares@ US$2.94Common StockSEC:0000905148-26-003353:0
7,429 shares@ US$2.97Common StockSEC:0000905148-26-003354:0
7,783 shares@ US$3.050.0012% mcap37.4% of flowCommonSEC144:0001974158-26-000091
9,475 shares@ US$3.050.0015% mcap5.5% of flowCommonSEC144:0001974158-26-000090
7,429 shares@ US$2.970.0011% mcap18.9% of flowCommonSEC144:0001974078-26-000273
4,644 shares@ US$2.940.0007% mcap23.9% of flowCommonSEC144:0001974078-26-000274
7,842 shares@ US$5.18460.0022% mcap100.0% of flowCommon StockSEC:0000905148-26-001862:0
7,542 shares@ US$5.19170.0021% mcap85.4% of flowCommon StockSEC:0000905148-26-001863:0
9,511 shares@ US$5.220.0027% mcap16.1% of flowCommon StockSEC:0000905148-26-001864:0
1,641 shares@ US$5.2040.0005% mcap44.7% of flowCommon StockSEC:0000905148-26-001865:0
4,697 shares@ US$5.22020.0013% mcap100.0% of flowCommon StockSEC:0000905148-26-001866:0
7,470 shares@ US$5.23710.0021% mcap78.2% of flowCommon StockSEC:0000905148-26-001867:0
24,367 shares0Common StockSEC:0000905148-26-001781:0
24,367 shares0Common StockSEC:0000905148-26-001782:0
24,367 shares0Common StockSEC:0000905148-26-001784:0
24,367 shares0Common StockSEC:0000905148-26-001785:0
24,367 shares0Common StockSEC:0000905148-26-001786:0
24,367 shares0Common StockSEC:0000905148-26-001787:0
24,367 shares0Common StockSEC:0000905148-26-001788:0
3,719 shares@ US$5.250144.9% of flowCommon StockSEC:0000905148-26-001384:0
2,816 shares@ US$5.24544.1% of flowCommon StockSEC:0000905148-26-001382:0
24,438 shares@ US$5.210229.7% of flowCommon StockSEC:0000905148-26-001381:0
3,719 shares@ US$5.121329.8% of flowCommon StockSEC:0000905148-26-001380:0
25 of 76 declarations
About Opus Genetics, Inc.
Opus Genetics, Inc. is a company focused on developing gene therapies for rare genetic diseases. It is listed on the XNAS market.